Core Viewpoint - BridgeBio Pharma, Inc. is set to release its fourth quarter and full year 2025 financial results and business updates on February 24, 2026, after market close, followed by a conference call to discuss these results [1]. Group 1 - The company focuses on developing medicines for genetic conditions, addressing the lack of treatment options for millions of people worldwide [3]. - BridgeBio employs a decentralized, hub-and-spoke model designed for speed, precision, and scalability in drug development [3]. - The company aims to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations [3]. Group 2 - A live webcast of the financial results presentation will be available on the BridgeBio website, with a replay accessible for 30 days post-event [2]. - Participants can register online to access the webcast [2]. Group 3 - Media and investor contacts for BridgeBio include Bubba Murarka, Executive Vice President, and Chinmay Shukla, Senior Vice President of Strategic Finance [4].

Core Viewpoint - Palatin Technologies, Inc. reported its financial results for the second quarter of fiscal year 2026, highlighting advancements in its MC4R-based obesity programs and a strengthened financial position through a successful public offering [1][2]. Financial Results - For the second quarter ended December 31, 2025, Palatin recognized $116,036 in collaboration and license revenue, a significant increase from $0 in the same quarter last year, attributed to the agreement with Boehringer Ingelheim [2]. - Total operating expenses were $7.4 million, up from $2.6 million in the comparable quarter last year, primarily due to increased costs in MCR obesity development programs and higher compensation costs [2]. - The net loss for the quarter was $7.3 million, or $(2.86) per share, compared to a net loss of $2.4 million, or $(5.92) per share, in the same quarter last year [2][4]. - As of December 31, 2025, cash and cash equivalents were $14.5 million, a significant increase from $1.3 million at the end of September 2025 [2][4]. Corporate Update - The company completed an $18.2 million public offering on November 12, 2025, which included the full exercise of the over-allotment option, allowing it to regain compliance with NYSE American listing standards [2]. - Palatin's obesity program focuses on developing differentiated MC4R agonists aimed at enhancing patient tolerability and addressing significant unmet medical needs in conditions like hypothalamic obesity and Prader-Willi syndrome [1][3]. - The company has initiated IND-enabling toxicology studies for its oral small-molecule MC4R agonist PL7737, with plans for clinical trial initiation in the first half of 2026 [1][3]. Obesity Program Update - PL7737 is expected to enter clinical evaluation in the first half of 2026, demonstrating meaningful weight loss and oral bioavailability in preclinical models [1]. - Next-generation selective peptide MC4R agonists are designed for once-weekly subcutaneous dosing, with clinical trials anticipated to start in the second half of 2026 [1]. - The obesity program aims to address rare and broader obesity indications, particularly focusing on neuroendocrine disorders [1][3]. Out-Licensing Programs Update - Collaboration with Boehringer Ingelheim for retinal diseases could yield up to €12.5 million ($14.5 million) in research milestones and up to €260 million ($307 million) in development and commercial milestones [1]. - The sublicensing agreement for PL9643, an MC1R agonist for dry eye disease, provided $3.8 million in upfront consideration, enhancing the company's financial position [1][2]. - Active out-licensing discussions are ongoing for PL8177 (ulcerative colitis) and diabetic nephropathy programs, reflecting interest from potential partners [1].

Core Insights - Dyadic Applied BioSolutions and Proliant Health & Biologicals have launched AlbuFree™ DX, a recombinant human albumin product utilizing Dyadic's proprietary technology, marking a significant step in Dyadic's commercialization strategy [1][2][3] Company Overview - Dyadic is a global biotechnology company focused on producing precision-engineered, animal-free proteins and enzymes for various applications, including life sciences and nutrition [1][5] - Proliant is a leading global producer of purified proteins, including albumin, serving life science and diagnostic markets with a well-established distribution network [1][6] Product Launch - The launch of AlbuFree™ DX highlights Dyadic's commitment to recombinant protein products with established commercial pathways and market demand [2][3] - AlbuFree™ DX is positioned to meet the rising demand for animal-free inputs in cell culture and life science applications, representing a key milestone in Dyadic's portfolio [3][4] Strategic Partnership - Under the agreement, Dyadic will receive a share of profits from Proliant's sales of recombinant human albumin products, reinforcing the partnership's commercial viability [2][4] - Proliant's extensive experience in albumin production and distribution supports the successful integration of AlbuFree™ DX into the market [4] Future Developments - Dyadic plans to expand its portfolio of recombinant proteins for various applications through internal programs and strategic partnerships, indicating a focus on scalable commercialization [4]

Core Viewpoint - NRx Pharmaceuticals has received guidance from the FDA indicating a potential path for New Drug Approval of NRX-100, a preservative-free ketamine formulation, aimed at treating patients with treatment-resistant depression, particularly those with suicidality [2][8]. Group 1: FDA Meeting and Guidance - NRx Pharmaceuticals completed an in-person Type C guidance meeting with the FDA, attended by leaders from the FDA Division of Psychiatry Products and the FDA Center for Drug Evaluation and Research [1][8]. - The FDA provided oral guidance suggesting that no additional nonclinical data or bridging studies would be required for the review of NRx's New Drug Application for NRX-100 [4][8]. Group 2: Drug Approval Pathway - Based on the guidance received, NRx believes it can file for New Drug Approval of NRX-100 using existing clinical trial data and Real World Evidence from over 65,000 patients [2][8]. - NRx plans to seek a broader indication for NRX-100 to include patients with treatment-resistant depression in the context of suicidality, rather than limiting it to just those with suicidality [2][8]. Group 3: Company Background and Drug Development - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal depression and PTSD [6]. - The company is also developing NRX-101, which has received Breakthrough Therapy Designation for treating suicidal bipolar depression [6].

Core Insights - AXPAXLI has demonstrated superiority over aflibercept in a Phase 3 trial for wet AMD, achieving significant visual acuity maintenance at both Week 36 and Week 52 [1][2][3] Group 1: Trial Results - The primary endpoint was met with 74.1% of subjects in the AXPAXLI arm maintaining vision at Week 36, showing a 17.5% risk difference (p=0.0006) compared to aflibercept [1][7] - At Week 52, 65.9% of subjects treated with AXPAXLI maintained vision, with a 21.1% risk difference (p<0.0001) compared to aflibercept [1][9] - Rescue-free rates for AXPAXLI were 80.6%, 74.7%, and 68.8% at Weeks 24, 36, and 52, respectively, compared to 72.1%, 56.4%, and 47.7% for aflibercept [1][11] Group 2: Safety Profile - AXPAXLI was generally well-tolerated with no treatment-related ocular serious adverse events (SAEs) reported [5][19] - The safety profile included a lower incidence of ocular adverse events compared to aflibercept, with only one SAE in the AXPAXLI arm [5][38] Group 3: Future Plans - The company plans to submit a New Drug Application (NDA) based on the SOL-1 data, pending discussions with the U.S. FDA [2][19] - Detailed results will be presented at the 49th Macula Society Annual Meeting scheduled for February 25-28, 2026 [16][20] Group 4: Mechanism and Technology - AXPAXLI is a bioresorbable intravitreal hydrogel incorporating axitinib, a multi-target tyrosine kinase inhibitor with anti-angiogenic properties [21][30] - The trial was conducted under a Special Protocol Assessment (SPA) agreement with the FDA, aiming for a superiority label for AXPAXLI in wet AMD [4][25] Group 5: Market Context - Wet AMD is a leading cause of severe vision loss, affecting approximately 14.8 million individuals globally, with current therapies facing challenges such as treatment burden and patient discontinuation [29] - AXPAXLI's potential to reduce treatment burden and improve long-term visual outcomes could lead to significant clinical adoption if approved [3][4]

Core Viewpoint - Axsome Therapeutics has reached a settlement with Alkem Laboratories regarding patent litigation over its product SUNOSI, allowing Alkem to market a generic version under specific conditions starting in 2040 [1][2]. Group 1: Settlement Agreement - Axsome will grant Alkem a license to sell a generic version of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted, or on or after March 1, 2040, if not [1]. - The settlement is a result of Alkem's submission of an Abbreviated New Drug Application to the FDA for a generic version of SUNOSI [1]. Group 2: Regulatory Review - The settlement agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice for review as required by law [2]. - Axsome is also involved in similar patent litigation against another party related to SUNOSI, which remains pending in the U.S. District Court for the District of New Jersey [2]. Group 3: Company Overview - Axsome Therapeutics focuses on treating central nervous system disorders and has a portfolio that includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness, and migraines [3]. - The company aims to address significant gaps in care and develop differentiated products to improve patient outcomes [3].

Core Insights - Entrada Therapeutics has progressed patients in Cohort 1 to the open label, Phase 2 portion of the ELEVATE-44-201 study, with data from Cohort 1 expected in Q2 2026 and Cohort 2 data by the end of the year [1][2] Company Overview - Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible [3] - The company utilizes its proprietary Endosomal Escape Vehicle (EEV™) technology to enhance the delivery of therapeutics, aiming to improve treatment outcomes for various diseases, including neuromuscular disorders [3] Clinical Study Details - ELEVATE-44-201 is a Phase 1/2 clinical study evaluating the safety and effectiveness of ENTR-601-44 for treating Duchenne muscular dystrophy (DMD) in patients with specific gene mutations [1][2] - The study has completed dosing for Cohort 1 at 6 mg/kg and is set to escalate to 12 mg/kg for Cohort 2, with plans for a third cohort at doses up to 18 mg/kg [1][2] - The FDA granted Rare Pediatric Disease Designation to ENTR-601-44 in December 2025, which may facilitate accelerated approval processes [2]

Core Insights - Cyclerion Therapeutics has received positive written feedback from the FDA regarding its CYC-126 Phase 2 Proof-of-Concept study for Treatment Resistant Depression (TRD) [1][3] - The company is on track to initiate the Phase 2 study in the second half of 2026, with patient enrollment beginning in Australia and the U.S. in 2027 [3][7] - A Clinical Advisory Board has been formed, consisting of key leaders in neuropsychiatry and anesthesiology to guide the development of CYC-126 [4][5] FDA Feedback and Study Design - The FDA provided clear guidance that supports the advancement of CYC-126's Phase 2 study design, which will utilize FDA-approved anesthetics and established safety data [3] - The planned study will be a randomized, double-blind, two-part clinical trial assessing safety, antidepressant efficacy, and durability of response using the Montgomery–Åsberg Depression Rating Scale (MADRS) [2] Clinical Advisory Board - The Clinical Advisory Board includes five internationally recognized experts in neuropsychiatry and anesthesiology, who will provide strategic guidance for CYC-126's development [4][5] - Notable members include Dr. Husseini Manji, Dr. Linda Carpenter, Dr. Lawrence Olanoff, Dr. Yuriy Bronshteyn, and Dr. Laeben C. Lester, each bringing extensive experience in their respective fields [6] Company Overview - Cyclerion is focused on developing treatments for neuropsychiatric diseases, with CYC-126 positioned as a cornerstone for future growth, addressing a significant unmet medical need in TRD [8]

Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Paris and Pa ...

Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD HEIDELBERG, Germany, Feb. 17, 2026 (GLOBE NEWSWIRE) -- FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression (TRD), today announces its recogni ...